|
|
||||||||
CUTTING EDGE |


* Section of Nephrology, Department of Internal Medicine, and Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;
Renal Division, Fujigaoka Hospital, Showa University, Yokohama, Japan; and
Renal Division, Veterans Affairs Medical Center, and Department of Medicine, Emory University School of Medicine, Atlanta, GA 30033
Perforin mediates target cell apoptosis by CTLs and NK cells. Although perforin expression correlates strongly with acute allograft rejection, perforin-deficient mice reject allografts with the same kinetics as wild-type recipients. In this study, we tested the hypothesis that while perforin is dispensable for acute rejection, it is essential for down-regulating the alloimmune response by inducing the apoptosis of host immune cells. Using a skin transplantation model, we found that perforin-deficient mice are resistant to the induction of allograft acceptance by agents that block T cell costimulation. Failure to induce allograft acceptance in these mice was observed irrespective of whether the alloimmune response was CD4 or CD8 T cell-mediated and could be attributed to defective apoptosis of activated CD4 and CD8 T cells. In contrast, perforin did not influence T cell proliferation. Therefore, perforin is an essential immunoregulatory molecule that may be required for the induction of transplantation tolerance.
This article has been cited by other articles:
![]() |
D. C. Gondek, V. DeVries, E. C. Nowak, L.-F. Lu, K. A. Bennett, Z. A. Scott, and R. J. Noelle Transplantation Survival Is Maintained by Granzyme B+ Regulatory Cells and Adaptive Regulatory T Cells J. Immunol., October 1, 2008; 181(7): 4752 - 4760. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Orilieri, G. Cappellano, R. Clementi, A. Cometa, M. Ferretti, E. Cerutti, F. Cadario, M. Martinetti, D. Larizza, V. Calcaterra, et al. Variations of the Perforin Gene in Patients With Type 1 Diabetes Diabetes, April 1, 2008; 57(4): 1078 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Galazka, A. Jurewicz, W. Orlowski, M. Stasiolek, C. F. Brosnan, C. S. Raine, and K. Selmaj EAE Tolerance Induction with Hsp70-Peptide Complexes Depends on H60 and NKG2D Activity J. Immunol., October 1, 2007; 179(7): 4503 - 4512. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Beilke and R. G. Gill Frontiers in Nephrology: The Varied Faces of Natural Killer Cells in Transplantation Contributions to Both Allograft Immunity and Tolerance J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2262 - 2267. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Clementi, A. Chiocchetti, G. Cappellano, E. Cerutti, M. Ferretti, E. Orilieri, I. Dianzani, M. Ferrarini, M. Bregni, C. Danesino, et al. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function Blood, November 1, 2006; 108(9): 3079 - 3084. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses J. Immunol., February 1, 2004; 172(3): 1380 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, J. C. Hylind, and R. W. Dutton Effector Cell-Derived Lymphotoxin {alpha} and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases Cancer Res., January 1, 2004; 64(1): 406 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Lakkis Transplantation tolerance: a journey from ignorance to memory Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1979 - 1982. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |